Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445206 | 0.78 | BRD4 (0.45) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL10514329 | 0.77 | CSNK2A1 (0.49) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL9802730 | 0.77 | BRD4 (0.47) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL9803168 | 0.75 | BRD4 (0.43) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL1266405 | 0.74 | CSNK2A1 (0.50) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL23537344 | 0.74 | LMNA (0.39) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL9803012 | 0.74 | HPGD (0.40) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL9802743 | 0.74 | HPGD (0.46) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL22870384 | 0.73 | PLK1 (0.49) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 | |
| SCHEMBL7430749 | 0.73 | NPC1 (0.44) | CSNK2A1PLK1PLK3SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | claimed |
| JP-1299273-A | — | — | None | — | — | JP | disclosed |
| US-6472408-B1 | TWO 5- AMINO-5,6,7,8-TETRAHYDROQUINOLINE FRAGMENTS JOINED TOGETHER BY A DIVALENT LINKING GROUP; CHOLINESTERASE INHIBITORS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) | 2002-10-29 | — | — | US | disclosed |
| US-20020156096-A1 | Dimeric compounds | HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, THE (HK) | 2002-10-24 | — | — | US | disclosed |
| EP-0489379-B1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5310914-A | Imination, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-05-10 | — | — | US | disclosed |
| US-5216164-A | Used for relieving memory dysfunction such as Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0489379-A1 | 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-10 | — | — | EP | disclosed |
| US-5110815-A | Alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-05-05 | — | — | US | disclosed |
| US-5068334-A | Analgesics and antipyretics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| JP-H01299273-A | MEDICINAL COMPOSITION CONTAINING QUINOLINE2,5-DIONE, NEW QUINOLINE2,5-DIONE AND ITS PRODUCTION | DR KARL THOMAE GMBH | 1989-12-04 | — | — | JP | disclosed |
| EP-0338228-A2 | Use of quinoline-2,5-diones in a medicament having an analgesic, antipyretic and/or antiphlogistic activity | Dr. Karl Thomae GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156096-A1 | Dimeric compounds | ACHE, BCHE, CHRNA5 | CSNK2A1 2297/4885PLK1 298/4885PLK3 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.